ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

SABS SAB Biotherapeutics Inc

2.94
0.00 (0.00%)
시간외 단일가
최종 업데이트: 20:00:03
15분 지연
기업명 주식 심볼 시장 주식 타입
SAB Biotherapeutics Inc SABS 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.00 0.00% 2.94 20:00:03
개장가 저가 고가 종가 전일 종가
2.94
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
21/05/202406:45GLOBESAB Biotherapeutics Announces Q1 2024 Financial Results and..
06/05/202420:15GLOBESAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of..
16/04/202420:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/04/202420:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/04/202420:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/03/202420:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/03/202423:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
09/03/202406:30EDGAR2Form 8-K - Current report
24/02/202406:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/02/202406:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/02/202422:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/02/202422:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/02/202421:53EDGAR2Form 8-K - Current report
02/02/202421:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
27/01/202406:15EDGAR2Form 8-K - Current report
27/01/202406:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/01/202407:00EDGAR2Form 8-K - Current report
24/01/202407:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
20/01/202406:21EDGAR2Form 8-K - Current report
03/01/202423:00EDGAR2Form 8-K - Current report
03/01/202406:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
18/12/202323:34EDGAR2Form DEF 14A - Other definitive proxy statements
09/12/202307:26EDGAR2Form PRE 14A - Other preliminary proxy statements
01/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202321:40EDGAR2Form 8-K - Current report
29/11/202321:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
29/11/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
29/11/202306:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202306:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202306:45EDGAR2Form 8-K - Current report
21/11/202307:00EDGAR2Form 8-K - Current report
21/11/202306:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/11/202321:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
15/11/202309:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202321:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202321:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
14/11/202306:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202321:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
04/11/202306:00EDGAR2Form S-3 - Registration statement under Securities Act of..
04/11/202305:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202306:00EDGAR2Form DEF 14A - Other definitive proxy statements
28/10/202306:00EDGAR2Form 8-K - Current report
25/10/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202320:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
21/10/202305:30EDGAR2Form PRE 14A - Other preliminary proxy statements
19/10/202320:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202320:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
03/10/202305:10EDGAR2Form 8-K - Current report
02/10/202320:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
22/08/202305:15EDGAR2Form S-3 - Registration statement under Securities Act of..